Union Bank of
bullish highUnion Bank of India reported a strong Q4 FY26 with net profit of ₹18,697 crore and recommended a dividend of ₹5 per share.
Read Union Bank of analysis →Side-by-side earnings comparison across financial stats, AI summaries, management guidance, risks, quotes, and accountability signals.
Union Bank of India reported a strong Q4 FY26 with net profit of ₹18,697 crore and recommended a dividend of ₹5 per share.
Read Union Bank of analysis →Niva Bupa delivered a strong Q4 FY26 with GWP growth of 27.4% to ₹9,433 crore, driven by retail health growth of 35% and market share expansion to 10.4% in Q4.
Read Niva Bupa Health analysis →Union Bank of India reported a strong Q4 FY26 with net profit of ₹18,697 crore and recommended a dividend of ₹5 per share. The bank achieved robust business growth, with gross advances up 9.74% YoY and a significant improvement in CASA ratio to 35.21% from 32.51% in September. Management highlighted a strategic shift from bulk deposits to retail term deposits and CASA, reducing bulk deposits by ₹70,000 crore. The bank also created a ₹700 crore contingency provision without impacting profit or capital. NIM compressed to 2.64% due to the December rate cut but management expects stabilization and gradual improvement. Credit cost was low at 23 bps for the year, with guidance of ~1% for FY27. Key risks include potential stress from West Asia disruptions and elevated SMA1 levels, though management sees no material impact yet. The bank targets 13-14% credit growth in FY27 while maintaining asset quality and profitability.
Niva Bupa delivered a strong Q4 FY26 with GWP growth of 27.4% to ₹9,433 crore, driven by retail health growth of 35% and market share expansion to 10.4% in Q4. PAT surged 80% to ₹366 crore, with combined ratio improving 160 bps to 101.4% on operating leverage. Management guided for sustained retail industry growth of 17-19% CAGR and expects combined ratio to reach ~99% by FY29, with expense ratio savings offsetting modest loss ratio uptick. Key risks include potential commission cap regulation and competitive pressure from GST-driven volume growth normalization.
CASA improved from 32.51% in September 2025 to 35.21% in March 2026, driven by focus on low-cost deposits.
Gross NPAs reduced significantly year-on-year, reflecting improved asset quality.
Net NPAs declined to 0.48%, indicating strong recovery and lower slippages.
Common Equity Tier 1 ratio improved from 14.98% to 15.69%, strengthening capital base.
Retail health growth exceeded industry average of ~30% in H2 FY26, driven by GST tailwind.
Market share in retail health increased from 9.0% in Q4 FY25 to 10.4% in Q4 FY26.
EoM ratio improved from 39.2% in FY25 to 33.7% in FY26 due to operating leverage.
Solvency ratio remained healthy at 2.49x as of March 2026, well above regulatory minimum.
Management expects to achieve 13-14% credit growth in FY27, in line with industry trends and better than the 9.74% YoY growth in FY26.
Management guidance growthManagement expects NIM to defend current levels and gradually improve, driven by CASA expansion and better asset-liability management.
Management guidance marginsManagement guided credit cost around 1% for FY27, up from 23 bps in FY26, reflecting normalization and prudent provisioning.
Management guidance marginsManagement indicated that PSLC fee income could return to ₹1,000 crore plus levels in FY27, similar to FY25, after a lower contribution in FY26.
Management guidance revenueManagement expects combined ratio to improve to ~99% by FY29, driven by expense ratio savings of 200-250 bps.
Management guidance marginsManagement reiterated view that retail health industry will grow at 17-19% CAGR over a 5-year horizon.
Management guidance growthManagement guided that loss ratio may increase by about 150 bps over time, offset by expense ratio improvements.
Management guidance marginsOngoing West Asia conflict could stress energy-sensitive sectors and remittance flows, though management sees no material impact yet.
medium · analyst_questionSMA1 loans nearly doubled sequentially, indicating potential stress in the near term, though management attributed it to migration from SMA2.
medium · data_observationFurther repo rate cuts could compress NIM, though management expects to defend margins through liability mix improvement.
low · management_commentaryTotal deposit growth of 2.72% YoY trailed credit growth of 9.74%, potentially constraining future loan growth if not addressed.
medium · analyst_questionRegulatory changes could cap commission rates, impacting distribution costs and growth. Management awaits clarity but believes single expense limit is preferable.
high · analyst_questionIndustry growth may moderate as the GST tailwind fades. Management expects stabilization at 17-19% CAGR, but near-term volatility is possible.
medium · analyst_questionGroup health loss ratio was ~60.5% for FY26, and IFRS loss components on onerous contracts could signal underwriting risk.
medium · data_observationWe are choosing growth with quality number one and with profitability.
We would like to defend our name we want to defend. We continued saying that and that is what we tried.
Our combined ratio for FY26 improved by 160 basis points to 101.4%.
Our retail health growth for the same period was in excess of 40%.